Biontech Se Sponsored Adr (BNTX) has released an update.
BioNTech SE reported a successful 2023 with €3.8 billion in revenues, a net profit of €0.9 billion, and a strong financial position, boasting €17.7 billion in cash and investments. The company delivered 400 million COVID-19 vaccine doses, advanced its oncology pipeline with several strategic partnerships, and expects to launch its first oncology product in 2026, targeting ten indication approvals by 2030. Looking forward, BioNTech projects 2024 revenues to be between €2.5 and €3.1 billion, while continuing to focus on developing novel therapies for cancer and infectious diseases.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
